Importance of medicine quality in achieving universal health coverage

被引:25
作者
Ozawa, Sachiko [1 ,2 ]
Higgins, Colleen R. [1 ]
Yemeke, Tatenda T. [1 ]
Nwokike, Jude I. [3 ]
Evans, Lawrence [3 ]
Hajjou, Mustapha [3 ]
Pribluda, Victor S. [3 ]
机构
[1] Univ N Carolina, UNC Eshelman Sch Pharm, Div Practice Adv & Clin Educ, Chapel Hill, NC 27515 USA
[2] Univ N Carolina, UNC Gillings Sch Global Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27515 USA
[3] US Pharmacopeial Convent USP, Promoting Qual Med PQM Program, Rockville, MD USA
来源
PLOS ONE | 2020年 / 15卷 / 07期
关键词
SUBSTANDARD DRUGS; POOR-QUALITY; COUNTRIES; SYSTEMS; ACCESS; COULD;
D O I
10.1371/journal.pone.0232966
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objective To assess the importance of ensuring medicine quality in order to achieve universal health coverage (UHC). Methods We developed a systems map connecting medicines quality assurance systems with UHC goals to illustrate the ensuing impact of quality-assured medicines in the implementation of UHC. The association between UHC and medicine quality was further examined in the context of essential medicines in low- and middle-income countries (LMICs) by analyzing data on reported prevalence of substandard and falsified essential medicines and established indicators for UHC. Finally, we examined the health and economic savings of improving antimalarial quality in four countries in sub-Saharan Africa: the Democratic Republic of the Congo (DRC), Nigeria, Uganda, and Zambia. Findings A systems perspective demonstrates how quality assurance of medicines supports dimensions of UHC. Across 63 LMICs, the reported prevalence of substandard and falsified essential medicines was found to be negatively associated with both an indicator for coverage of essential services (p= 0.05) and with an indicator for government effectiveness (p= 0.04). We estimated that investing in improving the quality of antimalarials by 10% would result in annual savings of $8.3 million in Zambia, $14 million in Uganda, $79 million in two DRC regions, and $598 million in Nigeria, and was more impactful compared to other potential investments we examined. Costs of substandard and falsified antimalarials per malaria case ranged from $7 to $86, while costs per death due to poor-quality antimalarials ranged from $14,000 to $72,000. Conclusion Medicines quality assurance systems play a critical role in reaching UHC goals. By ensuring the quality of essential medicines, they help deliver effective treatments that lead to less illness and result in health care savings that can be reinvested towards UHC.
引用
收藏
页数:15
相关论文
共 53 条
[11]   Map of different vaccine supply chain efficiency measures [J].
Haidari, Leila A. ;
Brown, Shawn T. ;
Wedlock, Patrick ;
Lee, Bruce Y. .
VACCINE, 2017, 35 (01) :199-200
[12]   The experiences of implementing generic medicine policy in eight countries: A review and recommendations for a successful promotion of generic medicine use [J].
Hassali, Mohamed Azmi ;
Alrasheedy, Alian A. ;
McLachlan, Andrew ;
Tuan Anh Nguyen ;
AL-Tamimi, Saleh Karamah ;
Ibrahim, Mohamed Izham Mohamed ;
Aljadhey, Hisham .
SAUDI PHARMACEUTICAL JOURNAL, 2014, 22 (06) :491-503
[13]   Combined Regional Investments Could Substantially Enhance Health System Performance And Be Financially Affordable [J].
Homer, Jack ;
Milstein, Bobby ;
Hirsch, Gary B. ;
Fisher, Elliott S. .
HEALTH AFFAIRS, 2016, 35 (08) :1435-1443
[14]   Availability, use, and affordability of medicines in urban China under universal health coverage: an empirical study in Hangzhou and Baoji [J].
Huang, Yunyu ;
Jiang, Youfen ;
Zhang, Luying ;
Mao, Wenhui ;
van Boven, Job F. M. ;
Postma, Maarten J. ;
Chen, Wen .
BMC HEALTH SERVICES RESEARCH, 2018, 18
[15]   Selling my sheep to pay for medicines - household priorities and coping strategies in a setting without universal health coverage [J].
Husoy, Onarheim Kristine ;
Molla, Sisay Mitike ;
Muluken, Gizaw ;
Marie, Moland Karen ;
Frithof, Norheim Ole ;
Ingrid, Miljeteig .
BMC HEALTH SERVICES RESEARCH, 2018, 18
[16]   Substandard drugs: a potential crisis for public health [J].
Johnston, Atholl ;
Holt, David W. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 78 (02) :218-243
[17]  
Kaddu G., 2018, STRENGTHENING REGULA
[18]   The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data [J].
Kaplan, Warren A. ;
Cardenas, Jorge ;
Mansilla, Cristian ;
Tobar, Tatiana ;
Wirtz, Veronika J. .
PLOS ONE, 2019, 14 (05)
[19]  
Kieny M -P, 2018, Delivering quality health services: a global imperative for universal health coverage
[20]   Poor-Quality and Counterfeit Drugs: A Systematic Assessment of Prevalence and Risks Based on Data Published From 2007 to 2016 [J].
Koczwara, Andreas ;
Dressman, Jennifer .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 106 (10) :2921-2929